Menu
No results found.
688068
Beijing Hotgen Biotech Co., Ltd. – SHA
📢 Scheduled Break in Updates
Please note that there will be no updates this week as I am taking a well-deserved holiday. Normal updates will resume on Saturday, 30th August. Thank you for your understanding.
Weekly Share Price & Valuation Overview
Market Overview
Open
228.0000
Close
227.4700
High
234.9400
Low
220.2800
Trend
0.85996
Beijing Hotgen Biotech Co., Ltd.
China
• SHA - Shanghai Stock Exchange
• 688068
• Currency: CNY
Beijing Hotgen Biotech Co., Ltd. engages in the research, development, manufacture, and sale of medical and public safety inspection products of in-vitro diagnostic products in the field of biomedicine. It offers drug detection, CDC, Up-conversion luminescence technology, colloidal gold, CLIA, sugar capture, microfluidic, and gene detection products for testing of intestinal microorganisms, gastrointestinal foodborne infections, insect-borne diseases, respiratory pathogens, infectious diseases, Ebola virus antigen, biological warfare agents, microorganisms, and mycotoxins. Beijing Hotgen Biotech Co., Ltd. was founded in 2005 and is based in Beijing, China.
Key strengths
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
Scale & Structure
Core size and share structure. TTM values unless noted. “Estimated” where reconciled from per-share × shares.
- Market Cap Total equity value of the company (share price × shares outstanding).
- CNY 21.09B
- Enterprise Value Operating value: market cap + total debt − cash.
- CNY 18.98B
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- CNY 488.02M
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- CNY 229.24M
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- CNY -92.30M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- CNY 5.17
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- -2.43
- Dividend Yield Annual dividend ÷ share price. Reconciled using dividend per share when available.
- 14.00%
- Shares Outstanding
- 92.71M
- Float Shares
- 59.56M
- Implied Shares Outstanding
- 92.71M
Profitability & Efficiency
TTM basis. “Reconciled” = numerator ÷ TTM revenue. Margins reflect latest TTM calculations.
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
-45.07%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
-18.91%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
46.97%
- Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
-
-45.09%
- ROA Return on assets: net income ÷ total assets.
-
-3.37%
- ROE Return on equity: net income ÷ shareholder equity.
-
-7.16%
Growth
Growth rates are YoY unless labeled QoQ.
- Revenue Growth Year-over-year revenue growth.
-
-19.70%
Liquidity & Solvency
Balance-sheet health. Debt metrics shown as latest ratios; D/E is a ratio (not %).
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 4.91
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 1.68
- Total Cash Cash and equivalents.
- CNY 1.22B
- Total Debt Short + long-term interest-bearing debt.
- CNY 50.23M
- Net Debt Net Cash Total debt − cash (negative = net cash).
- CNY -1.17B
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- -0.54
Cash Flow
Shown only when internally consistent; margins are TTM.
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- CNY -33.01M
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- CNY 73.66M
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
-6.76%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
15.09%
- Cash Conversion (OpCF/EBITDA)
- 0.36
Sharemaestro House View
Risk: 1
Sharemaestro internal risk profile (0–3, higher is safer).
Operational: 3
Operational quality/consistency (0–3, higher is better).
Composite Score: 1
Overall internal composite (0–3, higher is better).
Suggested Allocation: 1.67%
Indicative portfolio weighting suggestion based on house view.
Structural Insights
(experimental)
Ownership & Liquidity
Free Float
Proportion of shares available for public trading.
64.2%
Insiders
Shares held by company insiders (officers, directors).
34.5%
Institutions
Shares held by institutions (funds, pensions).
22.4%
Capital Structure
Potential Dilution
Increase in share count if options/convertibles exercise.
None detected
Net Debt
Total debt − cash (negative = net cash).
CNY -1.17B
-240.0% of revenue
Net debt relative to revenue — debt load vs business scale.
Resilience Score
0–100 composite of liquidity, leverage and cash conversion; higher is better. If inputs are unavailable, we estimate using proxies (Net debt vs revenue, Cash-to-Debt). It is a guide, not a rating.
77
Methodology Notes
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
As of: 2025-08-28 00:40
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.